Prognostic biomarkers and molecular targets provide treatment options for patients with metastatic/advanced melanoma; however, acquired resistance to some drugs still proves challenging.
Advanced, metastatic melanoma is an aggressive disease with a poor prognosis; but therapies targeting gene mutations may offer hope to some patients.
Results of a phase 1 trial may raise expectations for better outcomes with lower toxicity.
Melanoma is one of the fastest growing cancers, but it can be prevented. Patients can use these tips to decrease the risk of skin cancer.
This patient fact sheet describes the risk factors for and preventative measures to take against melanoma.
Help your patients learn what they can do to protect themselves from skin cancer with this patient fact sheet.
Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 8: ...
Melanoma is the most dangerous type of skin cancer, and the most deadly. It begins in the melanocytes, but may ...
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|